Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM6N05H)

Drug Name
BIO-11006 Drug Info
Indication
Disease Entry ICD 11 Status REF
Chronic obstructive pulmonary disease CA22 Phase 2 [1]
Non-small-cell lung cancer 2C25.Y Phase 2 [2]
Cross-matching ID
PubChem CID
11622197
TTD Drug ID
DM6N05H

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Myristoylated alanine-rich C-kinase substrate (MARCKS) TTHRM39 MARCS_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Myristoylated alanine-rich C-kinase substrate (MARCKS) DTT MARCKS 6.281 7.941 6.916 7.214
Myristoylated alanine-rich C-kinase substrate (MARCKS) DTT MARCKS 6.281 7.941 6.916 7.214
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 12 Disease of the respiratory system
Disease Class ICD-11: CA23 Asthma
The Studied Tissue Lung tissue
The Studied Disease Chronic obstructive pulmonary disease [ICD-11:CA23]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Myristoylated alanine-rich C-kinase substrate (MARCKS) DTT MARCKS 1.55E-01 -0.15 -0.28
Myristoylated alanine-rich C-kinase substrate (MARCKS) DTT MARCKS 8.74E-03 -0.18 -0.5
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT00648245) Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Inhibition of myristoylated alanine-rich C kinase substrate (MARCKS) protein inhibits ozone-induced airway neutrophilia and inflammation. Exp Lung Res. 2010 Mar;36(2):75-84.